Učinkovitost in najpogostejši neželeni učinki zdravljenja z zaviralci od ciklina odvisnih kinaz 4 in 6 (CDK 4/6) pri metastatskem raku dojke Overview of the efficacy and most common side effects of treatment with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in metastatic breast cancer

Povzetek

Zaviralci od ciklina odvisnih kinaz (CDK)4/6 so relativno nova tarčna zdravila pri raku dojk, ki jih uporabljamo pri hormonsko odvisnem HER-2 negativnem podtipu za bolnice z lokalno napredovalim ali razsejanim rakom. V registracijskih kliničnih raziskavah, kot tudi v vsakodnevni praksi, so se izkazali za učinkovita zdravila s sprejemljivim varnostnim profilom. V spodnjem prispevku bomo na kratko predstavili učinkovitost in najpogostejše neželene učinke zdravljenja z zaviralci CDK4/6 ter ukrepanje ob njihovem pojavu.

Abstract (Eng)

Cyclin-dependent kinase (CDK) 4/6 inhibitors are relatively new targeted drugs that are used in the treatment of hormone receptor-positive, HER2-negative subtype of locally advanced or metastatic breast cancer. In registration clinical trials as well as in everyday practice, it has been shown that they are effective and have an acceptable safety profile. In this article, we will shortly present the efficacy and most common side effects of treatment with CDK4/6 inhibitors as well as corresponding clinical interventions.